Russia has announced the development of ‘Enteromix’, the world’s first cancer vaccine built on mRNA technology, which has demonstrated 100% efficacy and safety in clinical trials.
The development is being hailed as a major medical breakthrough, offering renewed hope to millions of cancer patients across the globe.
According to researchers, Enteromix has already moved into early clinical use at select oncology centers in Russia while awaiting final approval from the Ministry of Health for nationwide distribution.
During clinical testing, the vaccine showed no significant adverse effects—a notable departure from conventional cancer treatments such as chemotherapy and radiation, which often cause severe side effects including hair loss, fatigue, and organ damage.
The vaccine uses mRNA technology, the same platform that powered several COVID-19 vaccines.
This method enables the body’s own cells to produce proteins that mimic those found on cancer cells, training the immune system to identify and destroy malignant cells with precision.
Unlike traditional therapies, Enteromix targets tumors selectively, sparing healthy tissue and significantly improving patient tolerance.
Enteromix is administered through a simple intramuscular injection, making it less invasive compared to complex cancer treatments.
It was developed by the National Medical Research Radiological Centre in partnership with the Engelhardt Institute of Molecular Biology (EIMB), two leading Russian institutions specializing in oncology and molecular medicine.
Medical experts believe Enteromix could benefit a wide spectrum of patients, including those suffering from lung, breast, colorectal, and pancreatic cancers.
It may also offer new options for individuals with hereditary cancer syndromes such as BRCA1/2 mutations, those with tumors resistant to chemotherapy, and even patients with compromised immune systems who typically struggle with conventional treatments.
If final clearance is granted, Enteromix could represent a turning point in global oncology, offering patients an alternative to harsh treatments while boosting survival rates and quality of life. Oncologists are optimistic that such vaccines may pave the way for a new generation of precision therapies, shifting cancer treatment from generalized approaches to personalized, targeted medicine.
